FRANK MCCORMICK - 21 Feb 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
21 Feb 2023
Net transactions value
$0
Form type
4
Filing time
23 Feb 2023, 18:56:45 UTC
Next filing
28 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +158,814 $0.000000 158,814 21 Feb 2023 Common Stock 158,814 $11.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.